These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35091456)

  • 1. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition.
    Ghosh N; Postow M; Zhu C; Jannat-Khah D; Li QZ; Vitone G; Chan KK; Bass AR
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.
    Borgers JSW; van Wesemael TJ; Gelderman KA; Rispens T; Verdegaal EME; Moes DJAR; Korse CM; Kapiteijn E; Welters MJP; van der Burg SH; van Houdt WJ; van Thienen JV; Haanen JBAG; van der Woude D
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38945553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
    Alserawan L; Anguera G; Zamora Atenza C; Serra López J; Martínez-Martínez L; Riudavets Melià M; Sullivan I; Barba Joaquin A; Majem Tarruella M; Vidal S
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial.
    Kulkarni T; Newton CA; Gupta S; Samara K; Bernstein EJ
    Pulm Ther; 2024 Sep; 10(3):331-346. PubMed ID: 39073523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
    Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O
    Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
    Mathias K; Rouhani S; Olson D; Bass AR; Gajewski TF; Reid P
    Oncologist; 2023 May; 28(5):440-448. PubMed ID: 36595378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibody profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study.
    Li S; Xu D; Murakoshi N; Yuan Z; Imaoka T; Tajiri K
    Front Immunol; 2024; 15():1423622. PubMed ID: 39324142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dataset for: Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune-related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Data Brief; 2024 Apr; 53():110062. PubMed ID: 38317734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes.
    Mesti T; Ceplak Mencin V; Mileva Boshkoska B; Ocvirk J
    Radiol Oncol; 2021 May; 55(3):354-361. PubMed ID: 33939899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
    Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
    Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
    Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
    BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies to Malondialdehyde-Acetaldehyde Are Detected Prior to Rheumatoid Arthritis Diagnosis and After Other Disease Specific Autoantibodies.
    Mikuls TR; Edison J; Meeshaw E; Sayles H; England BR; Duryee MJ; Hunter CD; Kelmenson LB; Kay Moss L; Feser ML; Wagner B; Parish MC; Deane KD; Thiele GM
    Arthritis Rheumatol; 2020 Dec; 72(12):2025-2029. PubMed ID: 32621635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.
    Akturk HK; Couts KL; Baschal EE; Karakus KE; Van Gulick RJ; Turner JA; Pyle L; Robinson WA; Michels AW
    JAMA Netw Open; 2022 Dec; 5(12):e2246400. PubMed ID: 36512357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy-Induced Immune-Related Adverse Events in Melanoma.
    Monson KR; Ferguson R; Handzlik JE; Xiong J; Dagayev S; Morales L; Chat V; Bunis A; Sreenivasaiah C; Dolfi S; Tenney DJ; Shao Y; Osman I; Weber JS; Kirchhoff T
    Clin Cancer Res; 2024 Oct; 30(19):4412-4423. PubMed ID: 39115425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.
    Mu-Mosley H; von Itzstein MS; Fattah F; Liu J; Zhu C; Xie Y; Wakeland EK; Park JY; Kahl BS; Diefenbach CS; Gerber DE
    Oncoimmunology; 2024; 13(1):2351255. PubMed ID: 38737792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
    Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab.
    Castel-Ajgal Z; Goulvestre C; Zaibet S; Arrondeau J; Bretagne M; Peyromaure M; Batteux F; Alexandre J; Goldwasser F; Huillard O
    Clin Genitourin Cancer; 2022 Oct; 20(5):e362-e368. PubMed ID: 35577731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
    Barth DA; Stanzer S; Spiegelberg J; Bauernhofer T; Absenger G; Posch F; Lipp R; Halm M; Szkandera J; Balic M; Gerger A; Smolle MA; Hutterer GC; Klec C; Jost PJ; Kargl J; Stradner M; Pichler M
    Cancer Med; 2022 Aug; 11(16):3074-3083. PubMed ID: 35297215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.